PD-1 therapy rechallange after adjuvant pembrolizumab in renal cancer – Uromigos

Uromigos shared on X:

” The uromigos Live 2024 meeting asked some questions.

Here is one about PD-1 therapy rechallange after adjuvant pembrolizumab in renal cancer. These 2 polls clearly show the 1 year gap from the time of adjuvant Pembrolizumab changes everything.

This is despite 2 negative randomised rechallange trials in advanced disease. Is there something special about a 1 year interval or the adjuvant setting.

Have the group got this right?”

Source: Uromigos/X